Status:

RECRUITING

The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC

Lead Sponsor:

University of Milano Bicocca

Collaborating Sponsors:

Università degli Studi del Piemonte Orientale Amedeo Avogadro

Niguarda Hospital

Conditions:

Hepatocellular Carcinoma

Recurrent Hepatocellular Carcinoma

Eligibility:

All Genders

18+ years

Brief Summary

Hepatocellular carcinoma (HCC) recurs in up to 60% of patients who undergo resection. Circulating tumor cells (CTC) have been advocated as promotors of the recurrence. However, their role as prognosti...

Detailed Description

Liquid biopsy may allow a better stratification of patients according to their estimated prognosis. As well in other tumors (e.g. breast cancer), molecular characterization is permitting not only to b...

Eligibility Criteria

Inclusion

  • Hepatocarcinoma diagnosis confirmed by radiology and committed to surgery (resection or OLT) with curative intent.
  • First diagnosis and first treatment of hepatocellular carcinoma.
  • BCLC 0 - A - B
  • Histological confirmation of hepatocarcinoma at the histological specimen.
  • Availability of a fresh frozen section of the tumor obtained during the surgical procedures

Exclusion

  • Other tumors in the clinical history.
  • Presence of autoimmune liver diseases (eg. sclerotising cholangitis, primary biliary cirrhosis etc.).
  • Patients treated with surgery in case of not-curative intent (palliation, best supportive care, etc).
  • Histopathological specimen of combined liver primary neoplasms (e.g. 'epatocolangiocarcinoma').
  • Patients previously treated for HCC with other therapies

Key Trial Info

Start Date :

February 7 2019

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

February 7 2026

Estimated Enrollment :

70 Patients enrolled

Trial Details

Trial ID

NCT04800497

Start Date

February 7 2019

End Date

February 7 2026

Last Update

January 17 2024

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Ospedale San Gerardo

Monza, MB, Italy, 20900

2

ASST Grande Ospedale Metropolitano Niguarda

Milan, Italy

3

Università del Piemonte Orientale

Novara, Italy

4

Humanitas Research Hospital

Rozzano, Italy

The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC | DecenTrialz